arrow_back Back to App

Safe Drugs: Ending Chinese Ingredients in Federal Drug Purchases

New regulations aim to enhance drug safety in the U.S. by requiring the labeling of ingredient country of origin. Additionally, starting in 2024, federal agencies will gradually limit purchases of drugs with active ingredients from China, which may impact the availability and cost of some medications.
Key points
Requirement to label the country of origin for each active ingredient in drugs, increasing transparency for consumers.
Gradual phasing out of drugs with Chinese active ingredients from federal health program purchases, including the Departments of Health and Human Services, Veterans Affairs, and Defense.
Beginning January 1, 2024, at least 60% of active ingredients in drugs purchased by federal agencies must originate from countries other than China, meeting FDA standards.
Beginning January 1, 2026, 100% of active ingredients in drugs purchased by federal agencies must originate from countries other than China, meeting FDA standards.
Temporary waivers for these requirements may be granted until January 1, 2027, if no alternatives are available.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3401
Sponsor: Sen. Cotton, Tom [R-AR]
Process start date: 2021-12-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

ABC Safe Drug Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3401.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-12-15.

What are the main provisions?

Key points include:

  • Requirement to label the country of origin for each active ingredient in drugs, increasing transparency for consumers.
  • Gradual phasing out of drugs with Chinese active ingredients from federal health program purchases, including the Departments of Health and Human Services, Veterans Affairs, and Defense.
  • Beginning January 1, 2024, at least 60% of active ingredients in drugs purchased by federal agencies must originate from countries other than China, meeting FDA standards.
  • Beginning January 1, 2026, 100% of active ingredients in drugs purchased by federal agencies must originate from countries other than China, meeting FDA standards.
  • Temporary waivers for these requirements may be granted until January 1, 2027, if no alternatives are available.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cotton, Tom [R-AR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Economy